PALISADE BIO, INC. 8-K

What Happened

• Palisade Bio, Inc. (PALI) filed an 8-K on June 11, 2026 disclosing that on June 10, 2026 the Board expanded from five to six directors and appointed Jordan Zwick to serve as a non‑employee director through the 2027 annual meeting. The Board also named Mr. Zwick to the Audit Committee and determined he is independent under Nasdaq and SEC rules.
• At the company’s Annual Meeting, shareholders approved the Amended and Restated 2021 Equity Incentive Plan (A&R Incentive Plan) and the Amended and Restated 2021 Employee Stock Purchase Plan (A&R ESPP). Copies of the amended plans were filed as exhibits to the 8‑K.

Key Details

• Appointment date: June 10, 2026; term runs until the 2027 annual meeting (or earlier if successor elected, death, resignation or removal).
• Board size increased from five to six directors.
• Committee assignment: Mr. Zwick will serve on the Audit Committee and satisfies Nasdaq/SEC independence requirements.
• Compensation: as a non‑employee director, Mr. Zwick will receive cash and equity under the company’s non‑employee director compensation policy, including an initial grant of restricted stock units with a grant value of $566,000, vesting in three equal annual installments.
• Corporate documents: the A&R Incentive Plan and A&R ESPP were approved by shareholders and are included as Exhibits 10.2 and 10.3 to the filing.

Why It Matters

• Board and oversight: adding an independent director who joins the Audit Committee can affect corporate governance and financial oversight — useful context for investors assessing board composition and controls.
• Compensation and equity plans: the initial $566,000 RSU grant is a material director compensation item and the approved amended equity and ESPP plans set the framework for future equity awards and employee participation. Investors tracking potential dilution, executive/board incentives, or changes to equity-based compensation should review the full plan documents (filed as exhibits) and the company’s proxy statement for detailed terms.
• No related-party transactions requiring disclosure were reported in connection with Mr. Zwick’s appointment, and the company entered an indemnification agreement in line with those for other directors.